Evidence map›Paper›PMID 22476558›Full record

ReviewWorld journal of urology2012

Prostate cancer epidemiology in the United States.

Otis W Brawley

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 144 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01859221 nacompletednot on this mapstarted 2013, after this paper: background citation

Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer

TypeinterventionalSponsorUniversity of FloridaRan2013 to 2022Enrolled39ConditionsOligometastatic Prostate CancerArmsStereotactic radiation
NCT02156414 completednot on this mapstarted 2013, after this paper: background citation

Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer in Bogota Colombia.

Typeobservational_patient_registrySponsorJaveriana UniversityRan2013 to 2014Enrolled135ConditionsSecondary Malignant Neoplasm of Lymph Node, Prostatic NeoplasmsArmsRadical Prostatectomy, Extended Lymphadenectomy
3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. African-American survivors of prostate cancer: a meta-synthesis of qualitative studies.Journal of cancer survivorship : research and practice · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Diagnostic accuracy ofThe British journal of radiology · 2019
    Pooled it
  7. Pooled it
  8. Guideline
  9. Trial
  10. Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Otis W BrawleyDepartment of Hematology and Medical Oncology, Emory University, American Cancer Society, Atlanta, GA, USA. Otis.Brawley@Cancer.Org

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is a significant public health issue in the United States. It is the most commonly diagnosed non-skin cancer and the second leading cause of cancer death. The American Cancer Society estimates that in 2011, 240,890 men were diagnosed with prostate cancer and 33,720 men died of it.

methodsA review of the peer-reviewed literature was conducted: American Cancer Society, National Cancer Institute Surveillance, Epidemiology and End Results. Program data were assessed to describe trends in incidence, mortality, and survival rates and look at other predictors of risk of prostate cancer diagnosis and death.

resultsSince 1985, there have been significant changing trends in prostate cancer incidence, mortality, and survival rates, as well as changes in the age distribution of the population diagnosed and even in the distribution of pathologies at diagnosis. Major risk factors for diagnosis include age, family history, race, and screening behavior.

conclusionWhile prostate cancer remains largely a disease diagnosed in older men (over age 65), screening has increased risk of diagnosis among men in their 40s and 50s. The incidence rates and 5-year survival rates are heavily influenced by the introduction of serum prostate-specific antigen (PSA) and widespread screening. The effects of PSA usage and screening on mortality rates are less certain. Outcome studies among men treated with radical prostatectomy show that greater than 30% relapse rates are common. This suggests that many men who are diagnosed with "localized early stage disease" actually have "apparently localized early stage disease," which is really low volume metastatic disease.

Indexed as

AgedAge DistributionHumansIncidenceMaleMiddle AgedProstatic NeoplasmsRacial GroupsRisk FactorsSurvival RateUnited States

Identifiers

PMID22476558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.